Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 71 trades. If we consider the specifics of each ...

Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket. The company also launched new 7.5-mg and 10-mg single-use vials, which cost $ ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...